These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands. Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875 [TBL] [Abstract][Full Text] [Related]
15. Hydrolytic behaviour and chloride ion binding capability of [Ru(η6-p-cym)(H2O)3]2+: a solution equilibrium study. Bíró L; Farkas E; Buglyó P Dalton Trans; 2012 Jan; 41(1):285-91. PubMed ID: 22051630 [TBL] [Abstract][Full Text] [Related]
16. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852 [TBL] [Abstract][Full Text] [Related]
17. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. Peacock AF; Parsons S; Sadler PJ J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668 [TBL] [Abstract][Full Text] [Related]